StemCell Therapy

Diabetic Peripheral Neuropathy Treatment Market research report is the new statistical data source added by A2Z Market Research.

Diabetic Peripheral Neuropathy Treatment Market is growing at a High CAGR during the forecast period 2020-2026. The increasing interest of the individuals in this industry is that the major reason for the expansion of this market.

Diabetic Peripheral Neuropathy Treatment Market research is an intelligence report with meticulous efforts undertaken to study the right and valuable information. The data which has been looked upon is done considering both, the existing top players and the upcoming competitors. Business strategies of the key players and the new entering market industries are studied in detail. Well explained SWOT analysis, revenue share and contact information are shared in this report analysis.

Get Sample Copy (Including FULL TOC, Graphs and Tables) of this report @:

https://www.a2zmarketresearch.com/sample?reportId=315642

Note In order to provide more accurate market forecast, all our reports will be updated before delivery by considering the impact of COVID-19.

Top Key Players Profiled in this report are:

Reata Pharmaceuticals Inc, KPI Therapeutics Inc, Achelios Therapeutics Inc, ViroMed Co Ltd, Novaremed Ltd, Commence Bio Inc, Grunenthal GmbH, Immune Pharmaceuticals Inc, Mitsubishi Tanabe Pharma Corp, Medifron DBT Co Ltd, Relief Therapeutics Holding AG, Celgene Corp

The key questions answered in this report:

Various factors are responsible for the markets growth trajectory, which are studied at length in the report. In addition, the report lists down the restraints that are posing threat to the global Diabetic Peripheral Neuropathy Treatment market. It also gauges the bargaining power of suppliers and buyers, threat from new entrants and product substitute, and the degree of competition prevailing in the market. The influence of the latest government guidelines is also analyzed in detail in the report. It studies the Diabetic Peripheral Neuropathy Treatment markets trajectory between forecast periods.

Get up to 30% Discount on this Premium Report @:

https://www.a2zmarketresearch.com/discount?reportId=315642

The cost analysis of the Global Diabetic Peripheral Neuropathy Treatment Market has been performed while keeping in view manufacturing expenses, labor cost, and raw materials and their market concentration rate, suppliers, and price trend. Other factors such as Supply chain, downstream buyers, and sourcing strategy have been assessed to provide a complete and in-depth view of the market. Buyers of the report will also be exposed to a study on market positioning with factors such as target client, brand strategy, and price strategy taken into consideration.

The report provides insights on the following pointers:

Table of Contents

Global Diabetic Peripheral Neuropathy Treatment Market Research Report 2020 2026

Chapter 1 Diabetic Peripheral Neuropathy Treatment Market Overview

Chapter 2 Global Economic Impact on Industry

Chapter 3 Global Market Competition by Manufacturers

Chapter 4 Global Production, Revenue (Value) by Region

Chapter 5 Global Supply (Production), Consumption, Export, Import by Regions

Chapter 6 Global Production, Revenue (Value), Price Trend by Type

Chapter 7 Global Market Analysis by Application

Chapter 8 Manufacturing Cost Analysis

Chapter 9 Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 10 Marketing Strategy Analysis, Distributors/Traders

Chapter 11 Market Effect Factors Analysis

Chapter 12 Global Diabetic Peripheral Neuropathy Treatment Market Forecast

Buy Exclusive Report @:

https://www.a2zmarketresearch.com/buy?reportId=315642

If you have any special requirements, please let us know and we will offer you the report as you want.

About A2Z Market Research:

The A2Z Market Research library provides syndication reports from market researchers around the world. Ready-to-buy syndication Market research studies will help you find the most relevant business intelligence.

Our Research Analyst Provides business insights and market research reports for large and small businesses.

The company helps clients build business policies and grow in that market area. A2Z Market Research is not only interested in industry reports dealing with telecommunications, healthcare, pharmaceuticals, financial services, energy, technology, real estate, logistics, F & B, media, etc. but also your company data, country profiles, trends, information and analysis on the sector of your interest.

Contact Us:

Roger Smith

1887 WHITNEY MESA DR HENDERSON, NV 89014

[emailprotected]

+1 775 237 4147

Visit link:
Impact of COVID-19 on Diabetic Peripheral Neuropathy Treatment Market 2020 | Size, Growth, Demand, Opportunities & Forecast To 2026 | Reata...

Coherent Market Insights has recently updated its massive report catalogue by adding a fresh study titled Global Diabetic Neuropathy Market: Industry Analysis, Size, Share, Growth, Trends, & Forecast 2018-2026. This business intelligence study On current Growth as well as future status during the mentioned forecast period of 2026.

The report also targets important facets such as market drivers, challenges, latest trends, and opportunities associated with the growth of manufacturers in the global market for Diabetic Neuropathy. the report provides the readers with crucial insights on the strategies implemented by leading companies to remain in the lead of this competitive market.

The Well-Established Players In The Diabetic Neuropathy Market are: Eli Lilly and Company, GlaxoSmithKline, Pfizer, Johnson & Johnson and Janssen Pharmaceuticals.

Get a Free PDF Brochure Of This Research Report @ https://www.coherentmarketinsights.com/insight/request-pdf/213

This research report also provides an overall analysis of the Diabetic Neuropathy Market share, size, segmentation, revenue forecasts, and geographic regions of the market along with industry-leading players are studied with product portfolio, capacity, price, cost and revenue. The research Diabetic Neuropathy report analysis on the market current applications and comparative analysis with more focused on the pros and cons of and competitive analysis of major companies.

The Diabetic Neuropathy Market report identifies the market dynamics and trends within the global and regional market considering numerous aspects including technology, supplies, capacity, production, profit, price and competition. Furthermore, this study highlights the company profiles and competitive landscape of the involved key players within the Diabetic Neuropathy Market.

The research report begins with the introduction of the global Diabetic Neuropathy Market comprising value chain analysis, sourcing strategy and downstream buyers. The report encompasses the statistical analysis of Diabetic Neuropathy Market cost, manufacturers, competition, and impact factors together with market forecast for 2018-2026. This analyzed study offers the buyer of the Diabetic Neuropathy report to gain an integrated picture of the competitive landscape and plan the business strategies accordingly.

Significant Point Mentioned in Global Diabetic Neuropathy Market Report:

Advancement Trend and Consumer Evaluation A good summary of this Diabetic Neuropathy industry are cited in an in-depth record in addition to the present Market trends and analysis.

Evaluation of Technical Data and Manufacturing Plants The power and also business manufacturing of the significant manufacturers of this has been within the technical data and even fabricating plants of this Market.

Manufacturing Price Structure Evaluation The department recorded for fabricating cost structure comes with a Diabetic Neuropathy brief analysis of the most significant manufacturers and providers of most essential information.

Competitive Evaluation Comprehensive lists of Diabetic Neuropathy supply and demand, gross profit, ingestion ratio, cost analysis, and production capacity are included in the report.

Competitive Landscape of Global Diabetic Neuropathy Industry:

key developments, financial details, product sales and gross margin, Diabetic Neuropathy business short-term and long-term marketing strategies and SWOT analysis of the companies. Diabetic Neuropathy Market players are focused on product innovations and want to expand their geographical footprint in upcoming years.

Get Your Copy at a Discounted Rate!!! Limited Time Offer!!! : https://www.coherentmarketinsights.com/insight/request-discount/213

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. ShahCoherent Market Insights1001 4th Ave, #3200Seattle, WA 98154Tel: +1-206-701-6702Email: [emailprotected]

Excerpt from:
Diabetic Neuropathy Market :How The Will Perform In Upcoming Years Based On Size, Share And Demand In Major Regions | 2020-2026 - The PRNews Portal

Many Americans, and indeed people all over the world, were outraged when reports surfaced this past summer that President Trump had once dismissed the dead soldiers from one of World War Is iconic battles, The Battle of Belleau Wood, as suckers and losers. Amputees should be excluded from parades because nobody wants to see them, the article also reports he had said.

The president denied these claims, but the outcry highlighted the high regard in which the American public, and most of the world, holds veterans; people are united by the pride and respect for those brave enough to risk life and limb for their country.

In the United States, the number of injured soldiers returning home alive has risen from 75% to 92% since the Vietnam War, but combat takes a toll on the survivors. Its estimated that one in every 10 veterans alive today was injured seriously while serving. And, for many, the nature of the injury makes treatment very difficult. Soldiers can find themselves returning home with severe burns, spinal cord injuries, paralysis, blindness, deafness, brain injuries and loss of limbs, as well as psychological trauma, some linked directly to physical injuries.

The most significant development in recent years for severely maimed veterans and other victims of physical injuries is the acceleration of whats known as regenerative medicine. Regenerative medicine was first defined in 1999 and it encompasses many disciplines of science. Its goal is to provide clinicians with the tools to effectively repair or replace a patients damaged tissues and organs in order to return normal function.

The technology really emerged into the public consciousness in the 2000s because of the Iraq war and, since then, great strides have been made in applying it to treating many different healthcare issues. So, what about the specifics? What are the most promising breakthroughs in recent years?

Some of the most challenging war-related injuries involve bones. Severe burns, spinal cord injuries, blast injuries, traumatic brain injuriesthese seemingly disparate traumas can each lead to a painful complication during the healing process called heterotopic ossification (HO).

A team at Michigan Medicines Department of Surgery is focusing its research on how the healing process often goes awry. The problem often emerges at limb amputation sites. Weeks after surgery or injury, abnormal bones often form within soft tissues like muscleplaces where theyre not supposed to be, causing the patient agonizing pain.

Theres no way to prevent it and once its formed, theres no way to reverse it, said Benjamin Levi, M.D, co-head of the research team at the Center for Basic and Translational Research at Michigan Medicines Department of Surgery.

There may be a solution thanks to a collaborative study between Levi and a research group led by Stephen Kunkel, Ph.D. at Michigans Department of Pathology. It had been theorized that HO could be linked to inflammation at the site of injury or surgery. The researchers built on this theory by studying the cells that are present at the early stages of HO.

Working with mice, they have been able to identify a specific protein that is responsible for sending the signals that trigger stem cells within the bone to start this process of uncontrolled tissue growth. By targeting this protein and stopping its action, it could be possible to stop the process in the first place. This would improve the quality of life for many injured veterans.

Treating HO is very much a case of prevention being better than cure. Progressing this discovery into a therapeutic setting could eventually provide doctors with a mechanism to stop HO before it has a chance to develop. It would be a game changer for many veterans who would otherwise be left with this agonizing condition.

Severe blast injuries and bullet traumas also leave many veterans needing implants or prosthetics to replace bone that has been lost to severe injury. If you break a leg, a doctor will put it in a cast and allow the natural healing process to occur. If its a severe break, you may need surgery. But when a soldiers bone is ripped apart by a gunshot or a blast, the damage to the network of cells within the bone is so severe that it often cannot heal on its own.

Regenerative medicine may provide a solution. After leaving the US Army more than 20 years ago, solider Luis Alvarez founded a firm at the Massachusetts Institute of Technology that developed a paint derived from key proteins that can trigger bone regeneration. The inspiration behind Alvarezs innovation?

During my time in Iraq, I witnessed service members who suffered traumatic injuries undergo amputations weeks or months after the initial wound, because there was no reliable method for regenerating the bone.

The technology developed by his company allows doctors to coat implants with specific proteins, allowing them to trigger regeneration, thus aiding recovery of the damaged tissue. They are making great progress and looking to have something ready for doctors to use in clinics by 2021. Its an inspiring story. The company is rolling out multiple therapies heading into clinical trials over the next two years.

The military is also starting to invest heavily in one of the most exciting avenues of regenerative medicine to help veterans replace lost tissue. Bioprinting uses human cells mixed with specially designed bioinks to 3D print tissue-like structures for the purpose of regenerating damaged body parts. Using bioprinting, scientists can build replacement grafts using a patients own stem cells, thus removing the issues associated with transplant rejection. The technology is still in its infancy but, thanks to recent military investment, scientists are now applying bioprinting to the generation of skin grafts to treat the severe burns that many veterans are afflicted with.

Treating severe burns is an incredibly difficult process and many rarely heal completely. Patients can be left with extreme scarring, tight and itchy skin and disfigurement. When the skin is severely burned the body focuses on preventing infection by closing the wound as quickly as possible. New skin is generated but the structure is vastly different to normal tissue.

A 5-year research project led by Prof Jeff Biernaskie at the University of Calgary Faculty of Veterinary Medicine has made a big step forward.

What weve shown is that you can alter the wound environment with drugs, or modify the genetics of these progenitor cells directly, and both are sufficient to change their behaviour during wound healing. And that can have really quite impressive effects on healing that includes regeneration of new hair follicles, glands and fat within the wounded skin.

This research could lead to new drugs that greatly improve the healing process.

It is clear from the number of veterans currently coping with a compromised quality of life that we need to do more to treat their injuries. It is estimated that the number of veterans currently living with these life changing injuries is in the millions and their healthcare needs come at an immense economic cost. Fortunately, there is now a much stronger horse in the race to a cure.

Regenerative medicine was estimated to draw nearly $15 billion in investments in 2017. That figure is predicted to rise to in excess of $79 billion by 2026. Those are serious resources, providing hope that our veterans will benefit in the decade ahead.

Sam Moxon has a PhD in regenerative medicine and is currently involved in dementia research. He is a freelance writer with an interest in the development of new technologies to diagnose and treat degenerative diseases. Follow him on Twitter@DrSamMoxon

Excerpt from:
Regenerative medicine and war: The next breakthrough in treating injured veterans? - Genetic Literacy Project

ATHENS A key question surrounding COVID-19 is if people who have had the virus gain some degree of long-term immunity. Ted Ross is leading a nationwide study to examine this pressing question. Ross is director of the University of Georgias Center for Vaccines and Immunology and professor of infectious diseases in the College of Veterinary Medicine.

The bodys response to every infection is unique, Ross said. In this study, we hope to determine how the body fights this novel virus and what, if any, protection the body develops following infection.

The team also hopes to examine immunological, demographic and medical risk factors and the part they play in recovery and infection outcome. Using blood draws and saliva samples, the researchers will monitor participants over the course of 24 months. The project, called SPARTA (SARS SeroPrevalence and Respiratory Tract Assessment), is funded by the NIH National Institute of Allergy and Infectious Diseases and the National Cancer Institute.

In Athens and Augusta, the study will establish and follow participants at higher risk of exposure to the SARS-CoV-2 virus, including local health care and emergency services providers, as well as faculty, staff and students at UGA. The group will total about 3,000 participants between 18 and 85 years of age and at least 50% of the participants will be members of minority populations, which have been impacted by COVID-19 at a higher rate than other groups.

UGA will participate with other teams of investigators from universities and health care providers around the country including Augusta University Medical Center, Mt. Sinai Medical Center in New York City, University of Chicago, University of Miami, University of Michigan at Ann Arbor, University of California at Los Angeles Harbor Medical Center, Washington University Medical Center in St. Louis, and St. Jude Childrens Research Hospital in Memphis.

The list is expected to grow as more institutions join the project. The data collected from these locations will be aggregated and compared for a nationwide view of immunity and recovery from COVID-19.

Read the original:
UGA leads study on COVID-19 post-infection immunity - The Albany Herald

Individuals who choose to participate in the study will be notified if their antibody results are positive or negative

COLUMBIA, Mo. Researchers at the University of Missouri are collecting survey data and voluntary blood samples from students, faculty and staff to study the prevalence of COVID-19 antibodies in the campus community.

The university wants to understand how well the community is responding to mitigation strategies and provide researchers with information about individuals' immune systems responses to the virus, according to a press release from the university.

The risk survey asks individuals about behaviors and activities they have engaged in during the past few months, as well as their perceptions about COVID-19 and its impact on various age groups, said Enid Schatz, professor and chair of the Department of Public Health in the MU School of Health Professions.

The second part of the study involves a blood draw to test for COVID-19 antibodies, so we are trying to see if we can make any connections between behaviors and antibody prevalence. This could potentially help inform us what things we are doing that seem to be working well or if there are any additional risk mitigation strategies we can think of to continue to make MU a safe place for our community to be.

Researchers are looking for a randomized sample, so they are emailing students, inviting them to be participate in the project. The blood draws will take place throughout the fall semester.

Those who test positive for the antibodies will now presumably have some degree of protection from the disease. However, the strength and length of that protection is still unknown at this time, said John Middleton, a professor in the MU College of Veterinary Medicine who specializes in epidemiology. By looking at how an individual's immune system responds to the infection over time, we can gather a lot of data that will help inform us about how to protect people going forward.

Middleton said if a vaccine were to become widely available, this antibody project might help inform researchers how long the immunity from a vaccine is expected to last or how often people should get vaccinated.

The data collected from this research could help inform us of what type of immunity a vaccine will need to stimulate, Middleton said. Understanding the immune response to natural infection will help inform us whether vaccines are expected to be effective. However, in the absence of a vaccine we are not currently defenseless, as social distancing, hand hygiene and face coverings continue to be effective strategies for reducing the spread of COVID-19.

Schatz added that individuals who choose to participate in the study will be notified if their antibody results are positive or negative. However, the university will only be made aware of the overall percentage of antibody prevalence and will not learn the identity of the individuals participating.

If we can better understand peoples perceptions and behaviors, we can design future intervention strategies based on those behaviors, Schatz said. Our goal is to not only better understand disease exposure and transmission in our community, but also to provide resources to those that need it."

Link:
Mizzou researchers collecting blood samples to study COVID-19 antibodies on campus - KSDK.com

They're highly trained animals there to do a job, not pets

Last year at my previous college, my roommate had an emotional support dog. When everyone on the dorm floor found out, all they wanted to do was pet and play with him. They did not realize that the dog was there for a purpose: to help my roommate.

Mah-E-Noor Baloch, junior biology major, said she gets a lot of misconceptions from having an emotional support animal.

People often assume that having an emotional support animal is somewhat of a joke, Baloch said. When I state that I have an emotional support animal or an ESA, I am met with amused smirks and sarcastic laughter.

She said people who she has spoken with regarding emotional support animals will call them glorified pets.

Baloch said people always assume that they can play with her animal.

While in certain settings its appropriate, like hanging out amongst friends at a social gathering or spending time with family at home, in others its not, Baloch said. Lexi was trained to notice my depression, oncoming panic attacks and PTSD episodes.

Baloch also said people try to nudge her side, pick her up or pet her themselves.

She said she has seen people trying to sneak animals onto campus, claiming that they are emotional support animals. Baloch said she has had to explain to people that her emotional support animal was doing a job and that she has felt invalidated by people because of the stigma around emotional support animals.

ESAs are definitely not glorified pets and the stigma around them needs to end, Baloch said. They are lifelines to people like me who suffer with depression and anxiety.

Charlie Powell, senior public information officer for WSUs College of Veterinary Medicine, said there are certain issues that people need to be aware of when it comes to emotional support animals.

One of the things that people have to remember about service animals and training though is typically their trainers dont want you to pet their animal, Powell said. Peoples natural inclination is to pet those animals like that.

Powell said another example of student accommodations is the lactation station in the veterinary college.

If you have to accommodate someone, you have to accommodate them, Powell said. Thats one of those things most of our students are not pregnant but we still make accommodations for those who are.

He said people will sometimes pretend that their pet is an emotional support animal.

I think we also both know that there are a number of people who abuse this privilege in many different ways, Powell said.

Powell said there are a lot of factors that go into bringing an emotional support animal into a work or school environment, such as biohazard awareness, sterilization, housing and cultural differences.

It is a situational type of thing that has to be assessed individually for each request, Powell said. I think when anything comes to societal change thats big like this, I think being able to slow down, think clearly and come up with a good plan is vital.

Individuals who own emotional support animals have a valid reason to do so. People need to realize that emotional support animals are not regular pets, and are there to do a job.

Read the rest here:
OPINION: Normalize having emotional support animals The Daily Evergreen - The Daily Evergreen

The Organization of the Black Sea Economic Cooperation (BSEC)

For the first time in a while, Ukraine has nominated its candidate for the post of BSEC Secretary-General (Organization of the Black Sea Economic Cooperation). This was reported by the press service of the Ministry of Foreign Affairs of Ukraine.

The choice fell on Ukraines Deputy Foreign Minister Vasyl Bodnar.

It is worth noting that the BSEC was founded in 1992 in Istanbul. The purpose of the organization is the development of economic cooperation and trade. The organization includes 12 countries: Azerbaijan, Albania, Bulgaria, Armenia, Greece, Georgia, Moldova, Russia, Romania, Serbia, Turkey, and Ukraine.

Ukraine chaired the BSEC back in 2013. In 2016, Ukraine went on a diplomatic dmarche due to Russia's chairmanship in the BSEC.

On July 1, 2017, Ukraine once again headed the BSEC, and in December - handed over the presidency to Armenia.

As we reported earlier, on September 2, the Ukrainian government terminated several agreements within the Commonwealth of Independent States(CIS).

"A separate block, which we have traditionally on the agenda - the withdrawal from the regular agreements within the CIS. In particular, we denounce the agreement on cooperation in veterinary medicine, as well as withdraw from the agreement on cooperation in sanitary protection of territories," the statement said.

Read the original here:
Ukraine nominates its candidate for Organization of the Black Sea Economic Cooperation Secretary-General's office - 112 International

Aim:Colorectal cancer (CRC) is the third most common cancer in Australia, and survival after diagnosis of metastatic disease is improving. Our aim was to assess trends in epidemiology, treatment, molecular testing and survival in patients with metastatic CRC (mCRC).

Methods:Clinical data from February 2013 to December 2018 was recorded in a prospective, observational, multicenter cohort study conducted in Queensland, Australia, examining clinical and molecular biomarkers in cases of mCRC.

Results:A total of 159 patients who had metastasis diagnosed after February 2013 were included in survival analysis. Median age at diagnosis was 63.9 years, but 29% had early-onset disease (diagnosis aged <50 years). Median overall survival was 2.5 years (95% confidence interval [CI], 2.2-3.0) for the 159 patients included in survival analysis. Independent factors correlated with poor prognosis included right-sided primary tumor, neutrophil-lymphocyte ratio >5, increased alkaline phosphatase level (ALP) and an increasing number of sites of metastatic disease. In contrast, metastasectomy was associated with improved overall survival (adjusted HR = 0.29 95% CI, 0.16-0.54), with similar survival between patients who had liver and non-liver metastasectomy sites. Half (10/20) of the BRAF mutant CRC were also microsatellite unstable. The proportion of detected mutations amongst tested samples increased over time for Kirsten Rat Sarcoma (KRAS; OR [per year] = 1.19; 95% CI, 1.01-1.39). Concurrently, the methods of molecular genetics testing employed in routine clinical practice changed towards the adoption of next-generation sequencing.

Conclusions:Metastasectomy in mCRC may be beneficial regardless of the anatomical site of metastasis. The adoption of next-generation sequencing techniques for molecular genetics testing coincided with a slightly increased rate of detection of KRAS and BRAF mutations, potentially reflecting greater test sensitivity. Further translational research is required in mCRC to define novel targets for treatment.

Keywords:cancer epidemiology; cancer genetics; colorectal; medical oncology; registry.

Read more here:
Trends in epidemiology, treatment and molecular testing of metastatic colorectal cancer in a real-world multi-institution cohort study - DocWire News

https://research-highlights.keio.ac.jp/

On 21 May, 2020, the Joint Research Coronavirus Task Force was launched in Japan to promote the development of a mucosal vaccine for COVID-19 based on advanced genomic analysis.

"We will analyze 600 blood samples taken from Japanese COVID-19 patients located in approximately 100 hospitals throughout Japan," explains Takanori Kanai of the Keio University School of Medicine, who leads the task force. "One of the goals of the research is to try to understand why the mortality rate due to COVID-19 has remained significantly lower in Japan than the United States and European countries. We think it may be related to genetic differences. We want to resolve this issue and share our results with our colleagues around the world."

Background and goals

This research is being undertaken by experts affiliated with Keio University, Tokyo Medical and Dental University, Osaka University, the Institute of Medical Science at the University of Tokyo, the National Center for Global Health and Medicine, the Tokyo Institute of Technology, Kitasato University, and Kyoto University.

"Our research team includes specialists in infectious diseases as well as other fields such as molecular genetics, computational science, and gastroenterology, which is my area of expertise, and is not directly related to epidemiology or infectious diseases," says Kanai. "This project was conceived by a small group of medical doctors and researchers without experience of handling infectious diseases. But the actual project is interdisciplinary, with members including ICU and medical care staff at university hospitals, community healthcare practitioners, immunologists, and even members of the general public. Ultimately, we want to contribute to society through medicine and science."

Working hypotheses for possible reasons for fewer COVID-19 deaths in Japan and Asia

The members of the task force compiled the following list of potential reasons for the low mortality rate in Japan: Japan's world-class medical system; a history of regular face mask use and attention to hygiene (including hand washing) in daily life; a culture of avoiding physical contact akin to social distancing; low expression of virus receptors; BCG vaccination; and differences in immune response due to differences in racial HLA and other polymorphisms.

Gathering samples and genetic information

The task force's goals are to establish a medical response system to predict who is at risk of contracting severe COVID-19 and develop a vaccine using proprietary technology. Genomic analysis technology is being employed to elucidate the genetic basis of the mechanisms that trigger COVID-19 infections to worsen, and thereby develop methods to fight the disease and develop a mucosal vaccine.

The team is focusing on the fact that the number of COVID-19 deaths per capita is far smaller in the Japanese population than it is in Western countries. The 600 blood samples are being studied by methods including high-resolution HLA analysis, SNP array and whole-genome sequence analysis, and T-cell repertoire analysis.

"Our analysis is being used to compare severe cases with mild and asymptomatic cases to identify genes that may be responsible for the exacerbation of COVID-19 in Japanese patients," explains Kanai. "Regarding vaccine development, predicting the target epitope is a major challenge. We are planning to use supercomputer simulations to identify potential antigens for SARS-CoV-2 based on our results for determining the genes that lead to severe cases of COVID-19 in Japanese patients."

Initial findings will be announced in September 2020

The task force plans to announce the initial findings of their research in September 2020. This will include the identities of the genes associated with triggering severe cases of COVID-19 among Japanese people that could be used to predict potential severity during early diagnostics.

"We want to use our results to produce guidelines to mitigate the dangers of overloading the medical care system during potential second or possibly third waves of COVID-19," says Kanai. "Furthermore, our immunological genetic information will be valuable for designing potential vaccines for SARS-CoV-2 for many Japanese people. We will share our results with colleagues in other countries so that they can use them to develop strategies to combat COVID-19 for their own populations."

About the researcher

Takanori Kanai Professor

Department of Gastroenterology and Hepatology, School of Medicine

Takanori Kanai graduated from the Keio University School of Medicine in 1988. Between 1989 and 2003 he held teaching positions at the Keio University School of Medicine, Keio Cancer Center, and Tokyo Medical and Dental University (TMDU). He has also held distinguished positions including as a committee member of the Harvard Medical Institute Educational Program at TMDU; Section Editor of the journal Inflammatory Bowel Diseases; Associate Editor of Journal of Gastroenterology; Editorial Board Member, American Journal of Physiology and Gastrointestinal and Liver Physiology; and Clinical Professor of Medicine (Visiting), TMDU. At the Keio University School of Medicine, he was appointed as an associate professor in 2007 and a professor in 2013, and he has been serving as a vice dean since 2017.

Links

COVID-19 taskforce https://www.covid19-taskforce.jp/en/home/

Takanori Kanai informationhttps://k-ris.keio.ac.jp/html/100002919_en.html

Further informationKeio UniversityOffice of Research Development and Sponsored Projects2-15-45 Mita, Minato-ku, Tokyo 108-8345 JapanE-mail: [emailprotected]

WebsitesKeio Universityhttps://www.keio.ac.jp/en/

Keio Research Highlightshttps://research-highlights.keio.ac.jp/

About Keio University

Keio University is a private, comprehensive university with six major campuses in the Greater Tokyo area along with a number of affiliated academic institutions. Keio prides itself on educational and research excellence in a wide range of fields and its state-of-the-art university hospital.

Keio was founded in 1858, and it is Japan's first modern institution of higher learning. Over the last century and a half, it has evolved into and continues to maintain its status as a leading university in Japan through its ongoing commitment to producing leaders of the future. Founder Yukichi Fukuzawa, a highly respected educator and one of the most important intellectuals of modern Japan, aspired for Keio to be a pioneer of new discoveries and contribute to society through learning.

SOURCE Keio University

Link:
Keio University Research: Combating COVID-19: Nationwide genomic analysis to study possible reasons for the low COVID-19 mortality rate in Japan -...

Toronto scientists have mapped the genes allowing cancer cells to avoid getting killed by the immune system in a finding that paves the way for the development of immunotherapies that would be effective for larger patient populations and across different tumour types.

"Over the last decade, different forms of immunotherapy have emerged as really potent cancer treatments but the reality is that they only generate durable responses in a fraction of patients and not for all tumour types," says Jason Moffat, a professor of molecular genetics in the Donnelly Centre for Cellular and Biomolecular Research at the University of Toronto who led the work.

The study also revealed the need for new therapy to take into account the genetic composition of tumours because of mutations in the cancer cells that can potentially make the disease worse in response to treatment, often referred to as cancer resistance mutations.

"It's very important to understand at the molecular level how cancer develops resistance to immunotherapies in order to make them more broadly available. Advances in systematic genetic approaches have let us key in on genes and molecular pathways that are commonly involved in resistance to therapy," says Moffat, who holds Canada Research Chair in Functional Genomics of Cancer.

In immunotherapy, a patient's own immune cells, known as T killer cells, are engineered to find and destroy cancer. But treatment resistance has precluded its use in most patients, especially those with solid tumours.

"It's an ongoing battle between the immune system and cancer, where the immune system is trying to find and kill the cancer whereas the cancer's job is to evade that killing," says Keith Lawson, a co-lead author completing a PhD in Moffat's lab as part of his medical training in the Surgeon-Scientist Program at U of T's Faculty of Medicine.

Tumour heterogeneity--genetic variation in tumour cells within and across individuals that can impact therapy response--further complicates things.

"It's important to not just find genes that can regulate immune evasion in one model of cancer, but what you really want are to find those genes that you can manipulate in cancer cells across many models because those are going to make the best therapeutic targets," says Lawson.

The team, including collaborators from Agios Pharmaceuticals in Cambridge, Massachusetts, looked for genes that regulate immune evasion across six genetically diverse tumor models derived from breast, colon, kidney and skin cancer. The cancer cells were placed in a dish alongside the T cells engineered to kill them, where the ensuing onslaught served as a baseline. The researchers next deployed the gene editing tool CRISPR to switch off one-by-one every gene in the cancer cells and measured the resulting deviations from the killing baseline.

They identified 182 "core cancer intrinsic immune evasion genes" whose deletion makes the cells either more sensitive or more resistant to T cell attack. Among the resisters were all the genes known to develop mutations in patients who stopped responding to immunotherapy, giving the researchers confidence that their approach worked.

Many of the found genes had no previous links to immune evasion.

"That was really exciting to see, because it means that our dataset was very rich in new biological information", says Lawson.

Genes involved in autophagy, a process when cells ramp up recycling their components to mitigate damage following stress, came up as key for immune evasion. This raises a possibility that cancer's susceptibility to immunotherapy could be boosted by targeting its autophagy genes.

But as the researchers delved deeper, they found that deleting certain autophagy genes in pairs rendered the cells resistant to T cell killing. It means that if a tumour already harbors a mutation in one autophagy gene, a treatment that combines immunotherapy with a drug targeting another autophagy gene could make the disease worse in that patient.

"We found this complete inversion of gene dependency", says Moffat. "We did not anticipate this at all. What it shows us is that genetic context, what mutations are present, very much dictates whether the introduction of the second mutations will cause no effect, resistance or sensitivity to therapy".

As more research explores combinatorial effects of mutations across different types of cancer cells, it should become possible to predict from a tumour's DNA what type of therapy will be most effective.

Reference: Lawson KA, Sousa CM, Zhang X, et al.Functional genomic landscape of cancer-intrinsic evasion of killing by T cells. Nature, 2020. doi:10.1038/s41586-020-2746-2

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Read more here:
182 Genes Identified That Regulate Interactions Between Cancer Cells and T Cells - Technology Networks

Molecular Biomarkers Market Overview 2020 2025

This has brought along several changes in This report also covers the impact of COVID-19 on the global market.

The risingtechnology in Molecular Biomarkers Marketis also depicted in thisresearchreport. Factors that are boosting the growth of the market, and giving a positive push to thrive in the global market is explained in detail.

Get a Sample PDF copy of the report @ https://reportsinsights.com/sample/66212

Key Competitors of the Global Molecular Biomarkers Market are: , Alere, Atossa Genetics, Biophysical, Abbott, BioCept, BioTheranostics, DiagnoCure, GenomeDx, Genomic Health, Gen-Probe, Life Technologies, 20/20 GeneSystems, Cynvenio, Dako (Agilent), Epic Sciences, Foundation Medicine, Genomic Health, Molecular Response, Nodality, PGD

Historical data available in the report elaborates on the development of the Molecular Biomarkers on national, regional and international levels. Molecular Biomarkers Market Research Report presents a detailed analysis based on the thorough research of the overall market, particularly on questions that border on the market size, growth scenario, potential opportunities, operation landscape, trend analysis, and competitive analysis.

Major Product Types covered are:GenomicsProteomicsOthers

Major Applications of Molecular Biomarkers covered are:MedicineBiologyOthers

This study report on global Molecular Biomarkers market throws light on the crucial trends and dynamics impacting the development of the market, including the restraints, drivers, and opportunities.

To get this report at a profitable rate.: https://reportsinsights.com/discount/66212

The fundamental purpose of Molecular Biomarkers Market report is to provide a correct and strategic analysis of the Molecular Biomarkers industry. The report scrutinizes each segment and sub-segments presents before you a 360-degree view of the said market.

Market Scenario:

The report further highlights the development trends in the global Molecular Biomarkers market. Factors that are driving the market growth and fueling its segments are also analyzed in the report. The report also highlights on its applications, types, deployments, components, developments of this market.

Highlights following key factors:

:-Business descriptionA detailed description of the companys operations and business divisions.:-Corporate strategyAnalysts summarization of the companys business strategy.:-SWOT AnalysisA detailed analysis of the companys strengths, weakness, opportunities and threats.:-Company historyProgression of key events associated with the company.:-Major products and servicesA list of major products, services and brands of the company.:-Key competitorsA list of key competitors to the company.:-Important locations and subsidiariesA list and contact details of key locations and subsidiaries of the company.:-Detailed financial ratios for the past five yearsThe latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Our report offers:

Market share assessments for the regional and country level segments. Market share analysis of the top industry players. Strategic recommendations for the new entrants. Market forecasts for a minimum of 9 years of all the mentioned segments, sub segments and the regional markets. Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations). Strategic recommendations in key business segments based on the market estimations. Competitive landscaping mapping the key common trends. Company profiling with detailed strategies, financials, and recent developments. Supply chain trends mapping the latest technological advancements.

Access full Report Description, TOC, Table of Figure, Chart, etc. @ https://reportsinsights.com/industry-forecast/Molecular-Biomarkers-Market-66212

About US:

Reports Insights is the leading research industry that offers contextual and data-centric research services to its customers across the globe. The firm assists its clients to strategize business policies and accomplish sustainable growth in their respective market domain. The industry provides consulting services, syndicated research reports, and customized research reports.

Contact US:

:(US) +1-214-272-0234

:(APAC) +91-7972263819

Email:[emailprotected]

Sales:[emailprotected]

See the original post:
Molecular Biomarkers Market Incredible Possibilities, Growth Analysis and Forecast To 2026 |112233 - The Daily Chronicle

LA JOLLA, Calif., Sept. 29, 2020 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate the endocannabinoid system, todayannounced the receipt of Ethics Committee approval in the U.K. for the Companys Cancer Appetite Recovery Study (CAReS) entitled A Phase 1/2 Trial of the Synthetic Cannabinoid ART27.13 in Patients with Cancer Anorexia and Weight Loss. Barry J. A. Laird, M.D. of the Institute of Genetics and Molecular Medicine at the University of Edinburgh and St. Columbias Hospice Reader in Palliative Medicine, will serve as the coordinating investigator. ART27.13 is a highly potent, peripherally restricted synthetic, dual cannabinoid agonist believed to target peripheral CB1/CB2 receptors, and has the potential to increase appetite and food intake. Artelo intends to initially develop ART27.13 as a supportive care therapy for cancer patients suffering from anorexia and weight loss.

Receiving Ethics Committee approval is an essential step towards commencing our CAReS trial in the UK, stated Steven D. Reich, M.D., Artelos Chief Medical Officer. We are very pleased to have Dr. Laird as our Coordinating Investigator as we believe that his extensive knowledge of and focus on palliative medicine as well as his direct expertise in clinical trials evaluating treatments for anorexia will be invaluable as we evaluate ART27.13. We are working diligently on securing the additional regulatory requisite approvals which will enable us to open our clinical sites and initiate patient enrollment later this year.

"As an academic clinician, I am passionate about improving symptoms in people with life-limiting illness and I am honored to be working with Artelo on this exciting program and the CAReS clinical trial, stated Dr. Laird. My teams overarching goal is to help find therapies which improve the care of patients with cancer and I look forward to evaluating the potential of ART27.13 to reduce the devastating symptoms and improve quality of life of those suffering from this disease."

About the CAReS Study CAReS is a Phase 1/2 clinical trial of the synthetic cannabinoid ART27.13 in patients with cancer anorexia and weight loss, which will enroll up to 49 subjects, initially in clinical trial sites located in the U.K. The primary endpoint in Phase 1 of the study is to determine the most effective and safe dose of ART27.13 to be utilized in Phase 2. The primary endpoint in Phase 2 of the study is to determine point estimates of activity of ART27.13 in terms of lean body mass, weight gain, and improvement of anorexia.

About ART27.13ART27.13 is a potent, peripherally restricted dual synthetic agonist of the CB1/CB2 receptors. Existing ART27.13 clinical data suggests meaningful potential for the treatment of cancer-related anorexia and weight loss. In five Phase I clinical studies including over 200 subjects, ART27.13 previously demonstrated a statistically significant and dose-dependent increase in body weight in subjects without cancer. Artelo plans to advance ART27.13 as a supportive care therapy for cancer patients suffering from anorexia and weight loss.

About Artelo Biosciences, Inc. Artelo Biosciences, Inc.is a San Diego-based biopharmaceutical company dedicated to the development and commercialization of proprietary therapeutics targeting the endocannabinoid system. Artelo is rapidly advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, post-traumatic stress disorder, pain, and inflammation. Led by proven biopharmaceutical executives collaborating with highly respected researchers and medical experts, the company applies leading edge scientific, regulatory, and commercial discipline to develop high-impact therapies. More information is available atwww.artelobio.comand Twitter:@ArteloBio.

Forward Looking Statements

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Companys product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and managements current beliefs and assumptions.

These statements may be identified by the use of forward-looking expressions, including, but not limited to, expect, anticipate, intend, plan, believe, estimate, potential, predict, project, should, would and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Companys filings with the Securities and Exchange Commission, including our ability to raise additional capital in the future. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by applicable securities laws.

Investor Relations Contact:Crescendo Communications, LLCTel: 212-671-1020Email:ARTL@crescendo-ir.com

Read more:
Artelo Biosciences Receives Ethics Approval to Commence its Cancer Appetite Recovery Phase I/II Clinical Study (CAReS) of ART27.13 for the Treatment...

Dublin, Sept. 29, 2020 (GLOBE NEWSWIRE) -- The "Anal Cancer - Pipeline Review, H2 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

Anal Cancer - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Anal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Anal Cancer (Oncology) pipeline guide also reviews the key players involved in therapeutic development for Anal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 1, 19, 18, 2 and 5 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.

Anal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

Reasons to Buy

Key Topics Covered:

Introduction

Anal Cancer - Therapeutics Assessment

Anal Cancer - Companies Involved in Therapeutics Development

Anal Cancer - Dormant Projects

Appendix

Companies Mentioned

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/jteb4n

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Read the original here:
Global Anal Cancer Pipeline Report 2020: Breakdown by Stage of Development, Drug Target, Mechanism of Action, Route of Administration and Molecule...

Urothelial carcinoma of the bladder (UCB) exhibits significant sexual dimorphism in the incidence, etiology, and response to intravesical immunotherapy. Environmental factors such as tobacco use and clinical management issues such as delayed presentation have widely been associated with sex differences in UCB outcomes. Emerging findings from immune checkpoint blockade trials are suggestive of differential outcomes in females compared with males. Sex-specific differences in the way immune system functions and responds to pathogenic insults are well established. As such, an in-depth understanding of the genetic and epigenetic factors contributing to sex-associated differences in response to immunomodulatory therapies is needed urgently for improved management of UCB.

To review the associations between patient sex and clinical outcomes, with a focus on the incidence, host intrinsic features, and response to therapies in UCB.

Using the PubMed database, this narrative review evaluates published findings from mouse model-based and clinical cohort studies to identify factors associated with sex and clinical outcomes in bladder cancer. A scoping review of the key findings on epidemiology, genetic, hormonal, immune physiology, and clinical outcomes was performed to explore potential factors that could have implications in immunomodulatory therapy design.

Sex-associated differences in UCB incidence and clinical outcomes are influenced by sex hormones, local bladder resident immune populations, tumor genetics, and bladder microbiome. In the context of therapeutic outcomes, sex differences are prominent in response to bacillus Calmette-Gurin immunotherapy used in the treatment of non-muscle-invasive bladder cancer. Similarly, with respect to tumor molecular profiles in muscle-invasive bladder cancer, tumors from females show enrichment of the basal subtype.

Among proposed tumor/host intrinsic factors that may influence response to immune-based therapies, patient sex remains a challenging consideration that deserves further attention. Evidence to date supports a multifactorial origin of sexual dimorphism in the incidence and outcomes of UCB.

In this review, we highlight the sex-associated host and tumor intrinsic features that may potentially drive differential disease progression and therapeutic response in urothelial carcinoma of the bladder.

European urology oncology. 2020 Sep 20 [Epub ahead of print]

Madhuri Koti, Molly A Ingersoll, Shilpa Gupta, Christa M Lam, Xue Li, Ashish M Kamat, Peter C Black, D Robert Siemens

Department of Biomedical and Molecular Sciences, Queen's University, Kingston, Ontario, Canada; Department of Obstetrics and Gynecology, Queen's University, Kingston, Ontario, Canada; Cancer Biology and Genetics Division, Queen's Cancer Research Institute, Queen's University, Kingston, Ontario, Canada; Department of Urology, Queen's University, Kingston, Ontario, Canada. Electronic address: ., Department of Immunology, Institut Pasteur, Paris, France., Department of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH, USA., Department of Urology and Surgery, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA., Department of Urology, Division of Surgery, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA., Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada., Department of Urology, Queen's University, Kingston, Ontario, Canada.

PubMed http://www.ncbi.nlm.nih.gov/pubmed/32967818

See the rest here:
Sex Differences in Bladder Cancer Immunobiology and Outcomes: A Collaborative Review with Implications for Treatment. - UroToday

Pune, Sept. 29, 2020 (GLOBE NEWSWIRE) -- The global genomics market size is projected to reach USD 82.60 billion by the end of 2027. The massive investments in the research and development of efficient products will have a massive impact on the growth of the market in the coming years.

According to a report published by Fortune Business Insights, titled Genomics Market Size, Share & COVID-19 Impact Analysis, By Type (Products (Instruments & Software and Consumables) and Services), By Technology (Polymerase Chain Reaction (PCR), Next Generation Sequencing (NGS), Microarray, Sanger Sequencing, and Others), By Application (Diagnostics, Research, and Others), By End User (Research Institutes, Healthcare Facilities & Diagnostic Centers, Pharmaceutical & Biotechnological Companies, Contract Research Organization (CROs)), and Regional Forecast, 2020-2027, the market was worth USD 18.85 billion in 2019 and will exhibit a CAGR of 19.5% during the forecast period 2020-2027.

Genomics is a concept that involves the human gene and sequencing for treatment and study of several diseases or potential diseases. The study of human genetics helps identify and track critical diseases, with equal focus on the qualities and behaviour of a specific individual. In the past few years, genomics has contributed to the growth of numerous similar branches including the popular precision medicine.

Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/genomics-market-100941

The massive investments in the research and development of genomics and genomic sequencing will have a positive impact on the growth of the overall market in the coming years. The presence of several large scale companies has had a massive impact on the growth of the market in recent years and the influx of start-ups will create opportunities for growth in the foreseeable future.

Recent Clinical Studies have Indicated the Potential of Genomics to Tracking Patterns of Covid-19 Spread

The recent coronavirus outbreak has created a sense of panic among businesses across the world. Although healthcare industry has witnessed a contrasting impact, as compared to a few other sectors, there has been a recent surge in the need for healthcare professionals. The lack of skilled labour is consequential to the hesitancy among workers due to the severity of the disease. Although there are several ongoing research activities associated with the treatment of the coronavirus, there has been little success in this field.

Accounting to increasing cases of Covid-19 across the world, researchers are focusing on implementing preventive and precautionary measures through newer concepts. The excessive research associated with the use of genomics in Covid-19 pandemic has yielded a few successful measures. As a result, genomics has recently attracted attention from across the world.

The whole world is fighting the novel coronavirus. Sectors and industries are devasted due to the major loss caused by COVID-19 in business. The authorities of several countries have initiated lockdown to prevent the spread of this deadly virus. Such plans have caused disturbances in the production and supply chain. But, with time and resolution, we will be able to combat this stern time and get back to normality. Our well-revised reports will help companies to receive in-depth information about the present scenario of every market so that you can adopt the necessary strategies accordingly.

To get to know more about the short-term and long-term impacts of COVID-19 on this market, please visit: https://www.fortunebusinessinsights.com/industry-reports/genomics-market-100941

Constant Product Innovations are Consequential to Increasing R&D Efforts

The report encompasses several factors that have contributed to the growth of the overall market in recent years. Among all factors, the increasing number of product innovations, driven by rising investments in the research and development of the product, has made the highest impact on the growth of the market. In April 2020, Eurofins announced the launch of a new product in the genome sequencing space.

The company introduced SARS-CoV 2 full length genome sequencing, a product that is categorized under the next-generation (NGS) sequencing category. Increasing number of such product innovations will have a positive impact on the growth of the overall market in the coming years.

North America to Emerge Dominant; Increasing Activities associated with Whole-genome Sequencing will Emerge in Favor of Market Growth

The report analyses the ongoing market trends across five major regions, including North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. Among all regions, the market in North America is projected to emerge dominant in the coming years. The increasing research activities associated with whole-genome sequencing by private companies as well as government organizations will contribute to the growth of the regional market.

As of 2019, the market in North America was worth USD 8.27 billion and this value is projected to rise at a considerable pace in the coming years. The market in Asia Pacific will derive growth form the efforts put in towards genetic sequencing by countries such as China.

Quick Buy - Genomics Market Research Report: https://www.fortunebusinessinsights.com/checkout-page/100941

List of companies profiled in the Genomics Market report:

Industry Developments:

February 2020: Nebula Genomic announced the launch of a new product that will offer whole genome sequencing at US$ 299 to its customers.

Have Any Query? Ask Our Experts: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/genomics-market-100941

Table of Contents:

TOC Continued.!

Get your Customized Research Report: https://www.fortunebusinessinsights.com/enquiry/customization/genomics-market-100941

Have a Look at Related Reports:

Next-Generation Sequencing (NGS) Market Share and Global Trend By Type (Products, Instruments & Software, Consumables, Services), By Application (Diagnostics, Research), By End User (Research Institutes, Healthcare Facilities & Diagnostic Centres, Pharmaceutical & Biotechnological Companies, Contract Research Organization) & Geography Forecast till 2026

Molecular Diagnostics Market Share and Global Trend By Product Type (Instruments Reagents & Consumables), Application (Infectious Disease, Blood Screening, Histology & Oncology), Technique (Hospitals Amplification, Hybridization & Sequencing Techniques), End User (Hospitals, Clinical & Pathology Labs) and Geography Forecast till 2025

Polymerase Chain Reaction (PCR) Market Share & Industry Analysis, By Type (Standard PCR, Real-time PCR, and Digital PCR), By Product (Instruments and Reagents & Consumables), By Indication (Infectious Diseases, Oncology, Genetic Disorders, and Others), By End User (Hospitals & Clinics, Pharmaceutical & Biotechnology Industries, Diagnostic Centers, and Academic & Research Organizations), and Regional Forecast, 2019-2026

Hormone Replacement Therapy (HRT) Market Share & Industry Analysis, By Therapy Type (Estrogen and Combinations Replacement Therapy, Growth Hormone Replacement Therapy, Thyroid Hormone Replacement Therapy), By Indication (Menopause, Hypothyroidism, Male Hypogonadism, and Growth Hormone Deficiency), By Route of Administration (Oral, Transdermal, and Parenteral), By Distribution Channel (Hospital Pharmacies), and Regional Forecast, 2019-2026

Heart Valves Market Share & Industry Analysis, By Product Type (Replacement (Aortic, Mitral, and Others), and Repair), By Valve Type (Tissue Valve and Mechanical Valve), By Procedure (Surgical and Transcatheter), By End User (Hospitals, and Specialty Clinics & Others), and Regional Forecast, 2019-2026

About Us:

Fortune Business Insights offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.

Contact Us:

Fortune Business Insights Pvt. Ltd. 308, Supreme Headquarters, Survey No. 36, Baner, Pune-Bangalore Highway, Pune - 411045, Maharashtra, India.

Phone:US :+1 424 253 0390UK : +44 2071 939123APAC : +91 744 740 1245Email: sales@fortunebusinessinsights.comFortune Business InsightsLinkedIn | Twitter | Blogs

Press Release: https://www.fortunebusinessinsights.com/press-release/genomics-market-9172

See the rest here:
Genomics Market to Rise at 19.5% CAGR and Reach USD 82.60 Billion by 2027; Advances in Diagnostic Applications will Lead to a Wider Product Adoption,...

Best listening experience is on Chrome, Firefox or Safari. Subscribe to Federal Drives daily audio interviews onApple PodcastsorPodcastOne.

This topic can get emotional: Should animals be used in medical research? Now recently I aired an interview that was critical of the Veterans Health Administration for its use of cats in research experiments related to the bodily functions of paraplegics. VHAdid submit a rebuttal statement but the agency has not responded to requests for an interview. Americans for Medical Progress is an organization that advocates in favor of the ethical use of animals in medical research.Executive Director of Paula Clifford andCommunications Director Jim Newman joinedFederal Drive with Tom Temin.

Tom Temin:Alright, lets get right to this. Can animals be ethically used for research? We know they are, but is this something that has value in medical research?

Paula Clifford:Absolutely. I started out in research as a veterinary technician. And at that time, I was just doing an externship. I was a student, and I thought I would do my externship and go and spend my career working at a veterinary hospital. But during that time, I found that as a veterinary technician, I could dedicate my life to taking care of the animals that actually take care of people and other animals through research with them.

Jim Newman:And my early career experience was working at universities. I first worked at an institution in Oregon and then I worked for a cancer center. And what I learned from those experiences is that animals play a tremendously important role in developing treatments, I literally watched as cancer medications were developed, or new ways to treat patients were created through animal studies, or discovered through animal studies. And so thats one of the reasons I remain involved in this field is that I had first hand experience seeing the importance of this kind of research.

Tom Temin:And how is this done such that the animals dont suffer too much, in general?

Paula Clifford:Animals in research are cared for, a very large team of animal care professionals. And this is everybody from highly trained animal care technicians that do their day-to-day care. So feed, water, cleaning, and daily observations. And then you have veterinary technicians like me, who will then respond to any abnormal report. So if you have an itchy mouse, or a dog thats not eating normally, or a monkey thats behaving differently, that gets triaged to the vet care team. So the veterinary technician will check the animals out and then report that to the veterinarian who will come and diagnose and treat the animal.

Tom Temin:Well, let me ask you this, are there industry standards in the research community for how animals should be treated? Is there some sort of a certification program or any kind of inspection oversight that happens in facilities where animals are used in research?

Paula Clifford:Absolutely. So under the Animal Welfare Act, most animals are covered under that act. And that requires the USDA the United States Department of Agriculture to do at least an annual unannounced inspection to make sure that the animal care is compliant with those federal laws. But not all animals are covered under that act. But most animals are covered under the PHS policy, which needs to be followed by any institution that receives any government funding.

Tom Temin:PHS stands for ?

Paula Clifford:Public Health Service. So the majority of animals are covered under one of those two things. But there are some animals that are not and theres another layer, which is a voluntary accreditation by AAALAC International, and that really holds institutions at even higher standards. And they follow really detailed animal care protocols in a document called the guide for laboratory animal use.

Tom Temin:Jim, anything to add?

Jim Newman:I would just add that in addition to all of those external controls, there are internal controls at every institution, so as you probably can guess, there are inspections of facilities, and those are surprise inspections, but they cant be inspected every single day. So every institution is required to have its own system for monitoring how animals are cared for. And when you hear about something that happens, which is a rare thing that often is because the institution itself said, oh, heres an issue we need to address. So there are actually internal controls, as well as external controls to help ensure that animals are treated well.

Tom Temin:Were speaking with Jim Newman, hes the communications director, and with Paula Clifford, the executive director of Americans for Medical Progress. And again, you cant speak for what happens inside Veterans Affairs, but in your observations over the years, have the federal facilities that use animals in testing and there are quite a number of them generally follow these guidelines, including the federal ones?

Jim Newman:Absolutely. In fact, I was looking a little bit at the VAs research and it stands out for many reasons. One is that 99% of the research that the VA does is in rats and mice. Now you hear a lot of talk about other animals, and thats because the animal rights groups like to talk about that. But 99% is in, again, rats or mice, and in those very rare cases where they study other animals such as cats or dogs, theres a good reason for that its because those animals are specifically necessary for the kinds of studies that are conducted and looking at the list of achievements from the VA is pretty remarkable. Theyve been able to help veterans who receive spinal cord injuries that help them breathe, help them cough to clear their breathing channels. Bladder control is another issue that happens when you lose, you know, the ability to move your limbs. Thats something theyve helped them with. Artificial pancreas, organ transplants the list is 20 or 30 major items that have been accomplished through animal studies. So the VAs research is incredibly remarkable. Anybody who would like to do some research on it should really look at their site, because what theyre doing his outstanding research that actually helps both veterans but also all Americans.

Tom Temin:And Paula, what is it that your organization does to kind of get this word out? I mean, Americans for Medical Progress could cover almost any topic.

Paula Clifford:Sure. So a lot of what we do is we actually help those working with the animals either on the animal care side or the researcher side, to help them tell their story and share with the public really what its like to work with animals and research, why, when and how animals are involved in research. We also do a lot of work with institutions to help them engage with the public and really share, you know, what is it about animals that make it so necessary and so important to advance biomedical progress?

Tom Temin:I once spoke to a dairy farmer in a story I did is a very young reporter very many years ago. And they had, I dont know, 50 or 60 cows in this barn. And at the end of the cows life, I said, what happens when the cow gets too old? They said, well it becomes meat. I said, but dont you kind of get attached to them? They all have names hanging on their necks. And the farmer it was the wife of the farmer, I guess she was a farmer, too said, Well, we just consider it their final gift to us when they become steaks. And so not to get too touchy feely here, but people that handle animals in experimental situations, what kind of relationship do they have with the animals, do you think?

Paula Clifford:Oh, gosh, I can tell you what I know for sure. You certainly do get attached. I can share personal stories. And theres, if you talk to anybody who works with animals in research, they also do get attached. They have names. And often they do have to be euthanized at the end of the study. Because in order to get the data from the study, you need to look at the cellular level, you need to maybe take out the heart or look at the bladder. So thats really difficult. Any area of veterinary medicine can be heartbreaking, theres really rewarding and happy times. And theres really emotional and sad times. So theres crying that happens as well, because you do get attached to the animals and the end of study does come but we know that like the dairy farmer, it is their final gift to us. And not only will they be helping the scientists with their data, but the humans that will benefit from the data. And often the advancements that happen for humans also go on to benefit our pets as well: Surgical techniques, vaccines, medicines and multiple other types of advancements.

Tom Temin:And Jim, I guess people that are involved in this kind of work are also pet owners themselves, arent they?

Jim Newman:Thats very true. A lot of people enter animal care, for instance, because they want to work with animals, they want to be up close with them every single day. And you know, Americans, I think the percentage of Americans that own pets and love their pets is incredible. And of course, that includes scientists and animal care technicians. And anybody who works in a research facility. People who work with animals at work, also love those animals at work and at home. And theres some assumptions that people who work with animals in a research setting dont like animals, thats actually the opposite. The truth is that they love the animals they care for. And they probably go home to some of the pets that they also love just as much.

Paula Clifford:Yeah. And just to add, in some cases, when the study is complete, and the animal does not need to be euthanized, they get adopted. So I adopted a dog from research. He was on a pacemaker study, and he lived with us. I adopted him at seven and he lived with us until he at the end of his life of 15. So theres countless stories of researchers and animal care staff, veterinarians, veterinary technicians that adopt the animals that are able to be adopted when their study has ended.

Tom Temin:Paula Clifford is executive director of Americans for Medical Progress. Thanks so much for joining me.

Paula Clifford:It was a pleasure, thank you so much.

Tom Temin:And Jim Newman is the communications director. Jim, thank you.

Jim Newman:Thank you, sir.

Tom Temin:Well post this interview at FederalNewsNetwork.com/FederalDrive. Hear the Federal Drive on demand. Subscribe at Apple Podcasts or Podcastone.

Link:
Are there ethical ways to use animals in medical research? - Federal News Network

Nine members of the Texas A&M Veterinary Emergency Team (VET) and six agents from the Texas A&M AgriLife Extension Service will be deploying to Butte County, California on Saturday to help care for animals displaced by the ongoing wildfires.

The VET deployed to the same area last December to provide oversight on sheltering, inventory and data management, veterinary medical support for injured and ill animals, and efforts to reunite animals with their owners.

Our deployment to the camp wildfires in December 2018 and January 2019 set the stage for this request, said VET director Dr. Wesley Bissett. We have a close working relationship with the community we are being deployed to and our capabilities are well known to them.

Our primary role will be to provide consistency in operational management and veterinary medical care, he said. They have an outstanding group of people at the local level and I know we will all work together for the sake of the animals, their owners, and Butte County, California.

The teams mission will be to support three area shelters that have taken in almost 500 animals that have been displaced by the wildfires. The VET will bring their experience in managing emergency shelters and situations to help ease the stress being put on the local responders. The initial team deploying includes four veterinarians, two veterinary technicians, and three logistics and support personnel.

Anytime you go into out-of-state deployments, there is an element of uncertainty that is based on being so distant from the impact area, Bissett said. There is always a discovery phase during which you work to understand, specifically, what is needed so that your team can contribute to the success of the jurisdiction you are serving.

This isnt the first time this year that the VET has assisted with the ongoing wildfire efforts. Dr. Deb Zoran, VET member and professor in the Texas A&M College of Veterinary Medicine & Biomedical Sciences, recently deployed to Oregon to assist with the Texas A&M Task Force search and rescue dogs working in a particularly hazardous area.

For updates on the deployment, follow the VET on Facebook (@TAMUVET) and Twitter (@tamuvet1) and at tx.ag/VETteam.

Link:
Texas A&M VET Mobile Team Deploying To California To Assist With Wildfire Relief - Texas A&M University Today

Molly the Fire Safety Dog, one of the bigger names on Dog Twitter, could use some help with vet bills after a medical emergency this weekend.

Molly is an 8 year oldDalmatian from Clarksville, Arkansas who puts together livestreamed (and in-person when pawsible) demonstrations on fire safety for elementary students around the US and Canada through her Keep Kids Fire Safe Foundation.

While doing a livestream on her Facebook page on Saturday night, she possibly had a seizure or a stroke, which meant rushing over to an emergency animal hospital two hours away and an overnight stay.

Her blood pressure was checked out overnight, and she needed to visit an animal ophthalmologist (eye doctor specializing in medical care) on Sunday afternoon, which was a branch of veterinary medicine we didnt realize existed.

Im sitting outside hoping and praying the doc has good news, Mollys mom Dayna Hilton toldDog ODayon Sunday afternoon.

Becausevet bills are pricey at the best of times, and emergency procedures especially so, they would welcome PayPal donationsif you have the means to donate.

Everyone is so supportive and friendly, our palPeytonReads said earlier this year while talking about the kindness of Dog Twitter. Its more than positiveit is genuinely heartfelt care and concern. We gather and celebrate when someone is happy. We gather and offer support when someone is sad.

Molly was able to return home on Sunday night, and seemed exhausted but calm in a photo she shared.

Goodnight, everyone. Thanks for all the love and prayers you have sent my way, she wrote in the caption.

Molly was one of the recipients of the2019 ACE Awards(the American Kennel Clubs Award for Canine Excellence) in the Exemplary Companion Dog category, and she had a small role in the 2019 documentarySuperpower Dogs.Shes also the official ambassador ofSuperpower Dogs,and the mascot of the Keep Kids Fire Safe Foundation.

Close to home within the River Valley region of Arkansas, though, shes still the firedog for the local volunteer fire department, so she doesnt let the fame get to her head, even if she is friends with Bunsen the Science Dog and Sampson the Service Dog, not to mention an array of high-profile human members of Dog Twitter like Ive Pet That Dogs Gideonand Britishpet artist Iain Welch.

We hope Molly the Fire Safety Dog feels better soon, and that the kindness of the Dog Twitter community can help out with her vet bills.

Follow this link:
Molly the Fire Safety Dog needs help with vet bills after medical emergency - Dog of the Day

As a veterinarian, on a daily basis, were covering the grounds of treating and diagnosing medical conditions and also doing any surgeries that are required, also interacting with clientele, doing a lot of preventative care, a lot of puppy kitten work as well as older patients, so theres a wide variety in what you do every day, she says.

Cline has honed in her analytical side over the years, relying more on her intuition and experience, but its not just the animals suffering to worry about.

In the case of the hamster, Cline also mentions the bond that had formed between a young girl and the pet.

Theres that kind of unconditional love that they give you, they have needs and you provide for them; you get that positive feeling from that, and theyre just total affection, total love really, but a different kind than human love, she says of the bond between animals and humans.

For her, the two are inseparable.

I guess I love people and I love pets too. Veterinary medicine gives me that combination where I can interact with people in that capacity which I just love, she explains.

Truth be told, Cline isnt keen about her semi-retirement and talking about it makes her uncomfortable. But the pandemic has dramatically changed some of what she loves most about her job.

I like to practise in a very personal way, I like to focus on the client thats in (the room) and that pet and not be pressured or stressed or time restricted, she says. Its really hard to let go completely.

So, shes letting herself down slowly.

Shell miss her co-workers and the community work through the hospital raising awareness and funding for the Farley Foundation, which provides monetary support for those who struggle to pay for veterinary care.

Occupying her time isnt going to be a challenge. Between playing saxophone in two bands the Lincoln County Band & Jimmy Marando Swing Band gardening, and weekending at the cottage, she still plans on fitting in some time at the hospital.

At home, its an empty nest with John (her three boys are now grown and moved out) but shell be seeing more of her fur children an active Jack Russell terrier rescue and a former stray kitten, Tiger, who is now a grown 17-year-old.

While one door is slowly closing, another remains open in Clines heart should another animal be in need of the care and compassion that has, for so long, defined her work.

Its just about being able to serve, being able to provide. I think I really like to see a problem and solve the problem, she says.

Its just who she is.

View original post here:
'Really hard to let go': Grimsby veterinarian easing into retirement after 32 years - Niagarathisweek.com

Siyo, my name is Jessica Rose Lambert. I am the daughter of Kimlyn Sneed Lambert and the late Douglas Allen Lambert. I am from the Birdtown community, and a 2014 graduate of Cherokee High School and 2017 graduate of WCU. It has always been my life-long dream of mine to become a veterinarian. I am currently in my second year of attending post-graduate school at North Carolina State University in Raleigh, earning my Doctor of Veterinary Medicine Degree. It is my hope that one day I may be able to come back to the Qualla Boundary and open my own veterinary practice there. I would love to one day be able to help the people on the reservation with their pet care needs. I would also like to encourage EBCI students to consider becoming a Veterinarian, it is a great profession if you love animals like I do. I would like to personally thank the Yogi Crowe Scholarship for helping with my costs of living in Raleigh and for helping to make my dream a reality. They have generously provided funding that makes it possible for graduate students like me to make ends meet while attending school. Thank you again so very much!

Jessica Lambert

N.C. State Vet School Class of 2023

Original post:
THANK YOU: Lambert says thank you to Yogi Crowe Scholarship - The Cherokee One Feather - Cherokee One Feather